Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Journal article
Lin B. et al, (2024), Lancet Diabetes Endocrinol
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Journal article
Neves JS. et al, (2024), Eur J Heart Fail
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Journal article
Koychev I. et al, (2024), Alzheimers Res Ther, 16
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
Journal article
DAKIN H. et al, (2024), Medical decision making
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2024), Diabetes Obes Metab
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Journal article
Gao N. et al, (2024), PharmacoEconomics
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
Journal article
Koychev I. et al, (2024), BMJ Open, 14
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Journal article
Adler AI. et al, (2024), Lancet
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL.
Journal article
Gooding KM. et al, (2024), Diabetes Res Clin Pract
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.
Journal article
Rao VN. et al, (2024), Am Heart J, 271, 123 - 135
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2024), J Diabetes, 16
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Journal article
Cardoso P. et al, (2024), Diabetologia
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Timing of SGLT2i initiation after acute myocardial infarction.
Journal article
von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Journal article
Taylor R. et al, (2023), Clin Sci (Lond)
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Journal article
Regan JA. et al, (2023), JCI Insight
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy.
Preprint
Peters AE. et al, (2023)
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Journal article
Maddaloni E. et al, (2023), Diabetes Metab Res Rev